Image de couverture de livre

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Grace Lai‐Hung Wong, Edward Gane, Calvin Q. Pan, Scott Fung, Mang M. Ma, Namiki Izumi, Shalimar, Seng Gee Lim, Wan‐Long Chuang, Rajiv Mehta, Young‐Suk Lim, Leland J. Yee, John F. Flaherty, Frida Abramov, Hongyuan Wang, Maria Buti
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Letters on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.” Authors' Reply
par: Grace Lai‐Hung Wong, et autres
Publié: (2025)

Letter on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment”
par: Yan Liu, et autres
Publié: (2025)

Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate
par: Jiwon Yang, et autres
Publié: (2025)

Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB
par: Seong Hee Kang, et autres
Publié: (2026)

Atherosclerotic Cardiovascular Risk in Patients with Chronic Hepatitis B: Tenofovir Disoproxil Fumarate Vs. Tenofovir Alafenamide: A Korean Nationwide Study
par: Jiwon Yang, et autres
Publié: (2026)

Real World Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Liver Transplant Recipients
par: Erdem Bektas, et autres
Publié: (2025)

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
par: Ping‐Feng Wu, et autres
Publié: (2024)

Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg‐Negative Chronic Hepatitis B
par: Cheng‐Hao Tseng, et autres
Publié: (2025)

Letter: Reconsidering Tenofovir Disoproxil Fumarate Use in Light of Emerging Safety Evidence
par: Priyadarshini Zula, et autres
Publié: (2026)

Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B
par: Xingfei Pan, et autres
Publié: (2025)

Safety of Tenofovir Disoproxil Fumarate Among Breastfeeding Infants of Patients With Chronic Hepatitis B: A Systematic Review
par: Kevin Pak, et autres
Publié: (2024)

BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV‐Infected Patients
par: Fernando Pérez-Calvo, et autres
Publié: (2025)

Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B
par: Log Young Kim, et autres
Publié: (2025)

Population Pharmacokinetic Simulations for Dose Optimization of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients with Moderate‐to‐Severe Renal Impairment
par: Apinya Boonpeng, et autres
Publié: (2024)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
par: Maria Buti
Publié: (2025)

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide ( B/F/TAF ) in people previously treated with darunavir‐based antiretroviral therapy
par: Rhianna Sheridan, et autres
Publié: (2026)

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
par: Xingfei Pan, et autres
Publié: (2025)

Comparative Efficacy and Renal Safety of Entecavir and Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B: A Retrospective Cohort Study From Vietnam
par: Thong Duy Vo, et autres
Publié: (2025)

Letter to the Editor: Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment
par: Zanzan Zhao, et autres
Publié: (2025)

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg ‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial
par: Qiumin Luo, et autres
Publié: (2026)

Dual Minimal Physiologically Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites in Humans
par: Weihua Jiang, et autres
Publié: (2025)

A Comparative Study of Entecavir and Tenofovir Alafenamide on Quantitative HBsAg Reduction in Patients With CHB
par: Jungnam Lee, et autres
Publié: (2026)

Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study
par: C. Busca‐Arenzana, et autres
Publié: (2024)

Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta‐Analysis
par: Ping‐Yu Hsu, et autres
Publié: (2025)

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
par: Maria Buti, et autres
Publié: (2024)

Comparison of the efficacy and safety of TAF, TDF, and LdT to prevent the transmission of hepatitis B in pregnant women: A retrospective study
par: Shufang Pan, et autres
Publié: (2024)

Letter: Methodological Flaws and Clinical Gaps—A Critique of TAF / TDF 5‐Year Data in East Asian CHB
par: Zhiyao Shi, et autres
Publié: (2025)

An Electrochemical Sensor for Tenofovir Monitoring
par: Abdellatif Ait Lahcen, et autres
Publié: (2025)

Cost‐Effectiveness of De Novo Combination of Tenofovir Alafenamide Fumarate and Peginterferon Alfa‐2b Versus Peginterferon Alfa‐2b Monotherapy of HBeAg ‐Positive Chronic Hepatitis B in China
par: Na Wei, et autres
Publié: (2026)

Letter: Concerns Regarding the Paradoxical Renal Outcomes in Patients Switching From Entecavir to Tenofovir Alafenamide in the Study by Ogawa et al.
par: Jingru Ge, et autres
Publié: (2026)

Dose proportionality and half‐life of tenofovir in hair samples from those with differing adherence to TDF or TAF‐based regimens monitored by directly observed therapy
Publié: (2024)

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?
par: Yao‐Chun Hsu, et autres
Publié: (2026)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
par: YaoYao Dai, et autres
Publié: (2025)

Pediatric Mesenchymal Tumor With MN1::TAF3 Fusion
par: Chikako Sato, et autres
Publié: (2024)

Impact of Tenofovir Alafenamide Sub‐Dermal Implant Insertion Site Scarring on Acceptability and HIV Prevention Preferences: A Prospective Cohort Study in Durban, South Africa
par: Tanuja N. Gengiah, et autres
Publié: (2026)

Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score‐Matched Study Using Linear Mixed‐Effects Models
par: Takashi Kumada, et autres
Publié: (2026)

DigiT4TAF -- Bridging Physical and Digital Worlds for Future Transportation Systems
par: Zipfl, Maximilian, et autres
Publié: (2025)

Harnessing the TAF1 Acetyltransferase for Targeted Acetylation of the Tumor Suppressor p53
par: Md Kabir, et autres
Publié: (2024)

The Pseudo‐Natural Product Tafbromin Selectively Targets the TAF1 Bromodomain 2
par: Sohan Patil, et autres
Publié: (2024)

Overexpression of TAF4B Promoted the Proliferation of Undifferentiated Spermatogonia in Cattleyak In Vitro
par: Yuan Tian, et autres
Publié: (2024)